Tea-Derived Flavan-3-Ol Dimers for Lipase Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current plant-derived lipase inhibitors are not sufficiently effective in inhibiting fat absorption and often have flavor and safety issues when used in foods and beverages, making them impractical for daily consumption.
Innovation Solution
Development of lipase inhibitors containing dimers of flavan-3-ols derived from teas, such as assamicains, theasinensins, and theaflavins, which are commercially available or extracted from green, black, and oolong teas, providing strong lipase inhibitory activity without compromising taste or safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If plant-derived lipase inhibitors are used, then fat absorption inhibition is achieved, but effectiveness is insufficient
Solution Approach 1:
The patent changes the chemical structure parameter from monomeric polyphenols to dimeric polyphenols (specifically flavan-3-ol dimers with galloyl groups). This structural parameter change results in significantly enhanced lipase inhibitory activity, with IC50 values 10-100 times lower than monomeric forms, thereby resolving the contradiction between reliability and productivity of fat absorption inhibition.
Solution Approach 2:
The patent employs composite polyphenol structures consisting of two flavan-3-ol units linked together with galloyl groups. This composite structure combines the benefits of multiple phenolic rings and hydroxyl groups, creating a synergistic effect that dramatically improves lipase inhibition effectiveness while maintaining natural plant-derived safety.
2Reliability
If concentrated plant extracts are used for lipase inhibition, then effectiveness improves, but flavor and safety issues arise
Solution Approach 1:
The patent extracts and isolates specific dimeric polyphenol compounds from natural plant sources (tea leaves, grapes, berries). By taking out only the active dimeric components rather than using crude extracts, the invention achieves high lipase inhibition effectiveness while eliminating unwanted flavor compounds and potential safety concerns associated with concentrated plant extracts.
Solution Approach 2:
The patent applies local quality by specifically targeting and enhancing the concentration of dimeric polyphenols with galloyl groups at particular molecular positions. This localized structural feature (galloyl substitution pattern) provides the key to high lipase inhibition activity while maintaining overall molecular stability and safety, allowing effective use in food applications without adverse flavor or safety effects.
3Reliability
If existing lipase inhibitors are used, then fat absorption is inhibited, but adverse side effects occur
Solution Approach 1:
The patent converts the naturally occurring polyphenolic compounds from plants into beneficial therapeutic agents. These naturally derived dimeric polyphenols, which would normally be considered ordinary dietary components, are shown to possess potent lipase inhibitory activity. By utilizing nature's existing compounds rather than synthetic alternatives, the invention achieves effective fat absorption inhibition without the adverse side effects associated with pharmaceutical lipase inhibitors.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The tea-derived dimers of flavan-3-ols effectively inhibit pancreatic lipase, reducing blood triglycerides and enhancing health without the adverse effects of existing treatments, making them suitable for use in tasty foods and beverages as well as pharmaceutical compositions.
Implementation Method 1
dimers of flavan-3-ols have strong lipase inhibitory activity
Data Source
AI summary
The present invention provides lipase inhibitors containing dimers of flavan-3-ols derived from teas as well as foods and beverages and medicines containing said inhibitors. More specifically, the present invention provides lipase inhibitors containing at least one of assamicains represented by the formula:wherein G represents a galloyl group;theasinensins represented by the formula:wherein R1 represents G or H, and R2 represents G; andtheaflavins represented by the formula:wherein R1 and R2 independently represent G or H; as well as foods and beverages and medicines containing said lipase inhibitors.